ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
Pride month at ProQR is an opportunity to celebrate and thank all of the LGBT+ people in our communities, including our employees, scientists, and doctors that made our research possible.
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.
